Business
Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference
Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10, at 3:00 p.m. PT 12th Annual LifeSci Partners Corporate Access Event,
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10, at 3:00 p.m. PT\n12th Annual LifeSci Partners Corporate Access Event, January 9-11\nNEW HAVEN, Conn., Dec. 19, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following investor and partnership conferences in January. These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.\n\n \n \n \n \n \n \n\n \nBiotech Showcase 2023 (January 9-11, 2023)Presentation Date/Time: Tuesday, January 10, 2023, at 3:00 p.m. PTCorporate presentation: Jennifer Good, President and CEO\nThe corporate presentation slides will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com.\n12th Annual LifeSci Partners Corporate Access EventDate: January 9-11, 2023Location: San Francisco, CAFor more information or to register, please click here.\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis. The Company reported statistically significant results from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in adults with IPF. Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).\nFor more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn.\nAbout HaduvioHaduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- a...